Capricor Therapeutics (CAPR)
Develops deramiocel for Duchenne muscular dystrophy and StealthX exosome therapies.
$8.60
vs last close−0.75 (−7.98%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 67.46% | 39.22M shares | |
|---|---|---|---|
| 196 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.87% | 504.8K shares | |
| 6 holders · as of Jun 29, 2026 | |||
| Strategic holders | 12.20% | 7.09M shares | |
| 1 holder · as of Sep 24, 2024 | |||
| Other | ≈ 19.47% | 11.32M shares | |
| remainder | |||
58.14M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
196 holders · 39.22M shares · 32 new positions · 105 increased · 47 reduced · 34 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 4.15M | 7.13% | +723.2K | Aug 7, 2026 |
| Tang Capital Management LLC | 4.10M | 7.05% | +700.0K | Aug 14, 2026 |
| Suvretta Capital Management, LLC | 4.09M | 7.04% | +274.2K | Aug 14, 2026 |
| State Street Corp | 3.40M | 5.84% | +1.22M | Aug 7, 2026 |
| Vanguard Capital Management LLC | 2.30M | 3.95% | +269.9K | Aug 13, 2026 |
| Goldman Sachs Group Inc | 1.58M | 2.71% | +666.2K | Aug 14, 2026 |
| Ra Capital Management, L.P. | 1.51M | 2.59% | 0 | Aug 14, 2026 |
| Boxer Capital Management, LLC | 1.40M | 2.40% | +805.2K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 6.60% | 3.42M | 13G | Feb 26, 2026 |
| Tang Capital Management, LLC | 6.60% | 3.40M | 13G | Jan 26, 2026 |
| BlackRock, Inc. | 6.50% | 2.97M | 13G | Feb 5, 2025 |
| State Street Corporation | 5.90% | 3.40M | 13G | Aug 7, 2026 |
| RA Capital Management, L.P. | 5.20% | 3.01M | 13G | Aug 3, 2026 |
| Millennium Management LLC | 5.10% | 2.94M | 13G | Sep 14, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 25, 2026 | Anthony Bergmannofficer: CHIEF FINANCIAL OFFICER | Sale | 24,100 | $30.38 | 11,223 |
| Jun 25, 2026 | Karen Krasneyofficer: EVP, GENERAL COUNSEL | Sale | 24,100 | $30.38 | 30,547 |
| Jun 24, 2026 | Anthony Bergmannofficer: CHIEF FINANCIAL OFFICER | Sale | 400 | $30.00 | 11,223 |
| Jun 24, 2026 | Karen Krasneyofficer: EVP, GENERAL COUNSEL | Sale | 400 | $30.00 | 30,547 |
| May 1, 2026 | Anthony Bergmannofficer: CHIEF FINANCIAL OFFICER | Sale | 25,000 | $31.70 | 8,223 |
| May 1, 2026 | Karen Krasneyofficer: EVP, GENERAL COUNSEL | Sale | 25,000 | $31.70 | 30,547 |
| Apr 2, 2026 | Karimah Es Sabardirector | Sale | 7,529 | $32.00 | 0 |
| Mar 31, 2026 | Anthony Bergmannofficer: CHIEF FINANCIAL OFFICER | Sale | 25,000 | $30.13 | 8,223 |
| Apr 1, 2026 | Karimah Es Sabardirector | Sale | 53,735 | $31.03 | 0 |
| Mar 31, 2026 | Karimah Es Sabardirector | Sale | 61,265 | $30.17 | 0 |
House and Senate disclosures
Not reported.